A group of serum biomarkers containing Gal-3 (BNP, Gal-3, GDF-15, sST2, OPG, miRNA 19b and 21) combined with imaging biomarkers (GLS) are going to be tested as a tool for accurately assessing the risk in AS patients with type 2 diabetes mellitus [75]. This evidence concerns the gene TNFRSF11B and diabetes mellitus.